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Abstract
Background: Recently, it has been suggested that enhancement of incretin effect improves cardiac function. We
investigated the effect of a DPP-IV inhibitor, des-fluoro-sitagliptin, in reducing occurrence of restenosis in carotid artery in
response to balloon injury and the related mechanisms.
Methods and Findings: Otsuka Long-Evans Tokushima Fatty rats were grouped into four: control (normal saline) and
sitagliptin 100, 250 and 500 mg/kg per day (n=10 per group). Sitagliptin or normal saline were given orally from 1 week
before to 2 weeks after carotid injury. After 3 weeks of treatment, sitagliptin treatment caused a significant and dose-
dependent reduction in intima-media ratio (IMR) in obese diabetic rats. This effect was accompanied by improved glucose
homeostasis, decreased circulating levels of high-sensitivity C-reactive protein (hsCRP) and increased adiponectin level.
Moreover, decreased IMR was correlated significantly with reduced hsCRP, tumor necrosis factor-a and monocyte
chemoattractant protein-1 levels and plasminogen activator inhibitor-1 activity. In vitro evidence with vascular smooth
muscle cells (VSMCs) demonstrated that proliferation and migration were decreased significantly after sitagliptin treatment.
In addition, sitagliptin increased caspase-3 activity and decreased monocyte adhesion and NFkB activation in VSMCs.
Conclusions: Sitagliptin has protective properties against restenosis after carotid injury and therapeutic implications for
treating macrovascular complications of diabetes.
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Introduction
A novel approach in the treatment of type 2 diabetes is to
harvest the actions of incretin hormones such as glucagon like
peptide (GLP)-1 and glucose-dependent insulinotropic peptide
(GIP). GLP-1 and GIP are gut peptides and are secreted in a
nutrient-dependent manner, stimulating insulin secretion glucose-
dependently. In rodents, these peptides promote pancreatic beta
cell proliferation and inhibit apoptosis, leading to expansion of
beta cell mass [1,2]. Further, GLP-1 improves glucose homeostasis
via additional actions on both glucose sensors, inhibition of gastric
emptying, food intake and glucagon secretion [3]. As such, GLP-1
administration potently stimulates insulin secretion and reduces
blood glucose level in human subjects with type 2 diabetes [4].
Dipeptidyl peptidase IV (DPP-IV) is the enzyme responsible for
the degradation of endogenous GLP-1 and GIP, rapidly cleaving
and inactivating GLP-1 and GIP into inactive metabolites [5].
Hence, one recent glucose-lowering strategic approach is to
enhance active incretin hormone levels and activity through the
development of selective DPP-IV inhibitors [6,7]. The approach in
both preclinical animal models of type 2 diabetes and in clinical
studies of patients with type 2 diabetes has shown to increase levels
of intact GLP-1 and GIP, ultimately leading to meaningful
improvements in overall glucose homeostasis [8–10].
Cardiovascular disease is the main cause of death in type 2
diabetes. Almost 80% of diabetes patients die from cardiovascular
diseases such as myocardial infarction or stroke. Primary coronary
intervention with stent implantation is now widely performed to
patients with symptomatic coronary artery diseases. Although the
PLoS ONE | www.plosone.org 1 April 2012 | Volume 7 | Issue 4 | e35007development of drug eluting stents have reduced the incidence of
restenosis after coronary intervention, restenosis of the intervened
vessel is still a critical issue of significant magnitude [11].
Interestingly, a recent paper proved that augmentation of GLP-
1 by inhibition of DPP-IV improved left ventricle performance in
response to stress in patients with coronary artery disease [12].
There is evidence suggesting effects of GLP-1 on various
cardiovascular risk factors [13]. However, whether DPP-IV
inhibition has a role in preventing restenosis after vascular injury
and more generally has potential anti-atherosclerotic properties
has not been adequately explored.
Plasma levels of matrix metalloproteinase (MMP) 2 and 9 are
increased in diabetic patients reflecting changes in extracellular
matrix (ECM) metabolism [14]. The expression and activity of
MMPs in diabetes thus far have been reported to correlate with
the macrovascular and microvascular complications seen in this
disease [15,16]. However, there have been no data available
about the role of DPP-IV inhibitor on MMPs in type 2 diabetic
patients.
Since the DPP-IV inhibitors have been shown to improve
glucose homeostasis, their profile relating to atherosclerosis should
also be elucidated. In relation to this, some of the cytokines
generated from fat cells, known as ‘‘adipocytokines’’, have been
reported to be associated with chronic diabetic complications
[17,18]. A central adipokine is adiponectin, the lower concentra-
tion of which is reported to increase risks of macrovascular
complications [17,19]. Until now, there have been limited reports
on adiponectin changes following treatment with DPP-IV
inhibitors. In addition, it has been reported that DPP-IV
interacting with caspase recruitment domain family, member 11
(CARD11 or CARMA1) leads to NFkB activation in T-cells [20].
NFkB is a common regulator that involves in the control of
proinflammatory genes and vascular smooth muscle cells prolif-
eration.
In the present study, we investigated the ability of a DPP-IV
inhibitor, des-fluoro-sitagliptin, in reducing occurrence of reste-
nosis after vascular balloon injury and the related mechanisms by
applying a model of obese animals with naturally developing type
2 diabetes and vascular cell lines.
Methods
Study Animals and Care for the Animals
Forty Otsuka Long-Evans Tokushima Fatty (OLETF) rats (5
week old, male), the animal model for obese, type 2 diabetes, were
donated by the Japanese Otsuka Pharmaceuticals. OLETF rats
naturally develop type 2 diabetes around 24 weeks of age and have
been applied in studies investigating glucose metabolism and
cardiovascular complications [21]. A DPP-IV inhibitor des-fluoro-
sitagliptin (Merck, NJ, USA) was administered to twenty-four
weeks old OLETF rats to test the hypothesis that sitagliptin can
reduce the restenosis in carotid artery after balloon injury. Rats
were grouped into four groups: 1) Control (saline), 2) Sita100
(sitagliptin 100 mg/kg per day), 3) Sita250 (sitagliptin 250 mg/kg
per day), and 4) Sita500 (sitagliptin 500 mg/kg per day) (n =1 0
per group). Sitagliptin or normal saline were given orally for 1
week before and 2 weeks after carotid injury by using an oral
Zonde needle (Natsume, Tokyo, Japan).
Another 20 Long-Evans Tokushima Otsuka (LETO) rats, a
normal counterpart of the OLETF rat, were also donated by the
Otsuka Pharmaceutical Co. (Tokushima, Japan). Sitagliptin
(500 mg/day) or normal saline was administered to the rats (n
= 10 in each group) for 3 weeks to test the same hypothesis in this
normal control animal.
Animals were handled in compliance with the Guide for
Experimental Animal Research from the Laboratory for Exper-
imental Animal Research, Clinical Research Institute, Seoul
National University Hospital. Seoul National University Hospital
Ethics Committee for Animal Study approved this study (07177).
Animal Study
(1) Active GLP-1 and glucagon levels in plasma of
study rats. After 3 weeks treatment of sitagliptin, plasma active
GLP-1 levels were measured by an enzyme immunoassay
(RENDO-85K, Linco Research, St. Charles, MO, USA). After
collecting blood samples, tube was inverted several times to mix,
and 10 mL of DPP-IV inhibitor (Millipore) per every ml of blood
collected was added immediately. Then the blood was centrifu-
gated for 10 minutes at 1000 6 g after clotting for 30 minutes.
Plasma glucagon level was measured by the same kit (RENDO-
85K, Linco Research).
(2) Rat carotid artery balloon denudation injury. A
previously well-established rat carotid artery balloon injury model
was used in this study [22]. Rats were anesthetized with a
combination anesthetic (ketamine, 70 mg/kg; xylazine, 7 mg/kg
IP; Yuhan Corp, Seoul, Korea). After the left external carotid
artery was exposed, heparin (35 IU) is administered systemically
via the external jugular vein. A 2F Fogarty embolectomy catheter
(Baxter Healthcare Corp, IL, USA) was introduced into an
external carotid arteriotomy incision, advanced to the common
carotid artery, and inflated with 0.2 mL of saline and withdrawn
10 times with rotation.
(3) Morphometric analysis. Two weeks after balloon
injury, rats were euthanized with a lethal dose of pentobarbital,
and carotid arteries were fixed by perfusion at 120 mmHg with
4% formaldehyde via an 18G intravenous cannula placed
retrograde in the abdominal aorta. Tissues were then embedded
in paraffin, and sections were stained with H&E. The extent of
neointimal formation in histologically stained sections was
quantified by computed planimetry. The cross-sectional areas of
the blood vessel layers, ie, the lumen, intimal, and medial areas,
are quantified in 3 different sections (proximal, middle, and distal)
using an Image-Pro Plus Analyzer Version 4.5 (Media Cybernet-
ics, MD, USA). The intima-media ratio (IMR) was calculated from
the mean of these determinations.
(4) Immunoblot analysis for DPP-IV and GLP-1
receptors in carotid artery. Harvested vessel tissues were
homogenized with cell lysis buffer (Cell signaling, Beverly, MA,
USA) containing 20 mM Tris (pH 7.5), 150 mM NaCl, 1 mM
Na2EDTA, 1% Triton, 2.5 mM sodium pyrophate, 1 mM b-
glycerophosphate, 1 mM Na3VO4, 1 mg/mL leupeptin, and
1 mM PMSF for 30 minutes at 4uC and protein lysate
concentrations were measured by Bradford protein assay kit
(BioRad, Hercules, CA, USA). The same amounts of proteins
from whole cell lysates were subjected to sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS-PAGE) and transfer onto
methanol-treated PVDF membranes (Millipore Co, Bedford, MA).
After blocking the membrane with Tris-buffered saline-Tween 20
(TBS-T, 0.1% Tween 20) containing 5% blocking buffer for 1
hour at room temperature, they were washed with TBS-T and
incubated primary antibodies, DPP-IV (Santa Cruz, CA), GLP-1-
receptor (Santa Cruz) and c-tubulin (Sigma, St Louis, MO) for 1
hour at room temperature or for overnight at 4uC. The
membranes were washed three times with TBS-T for 10 minutes,
and then incubated for 1 hour at room temperature with
horseradish peroxidase (HRP)-conjugated secondary antibodies.
Sitagliptin and Atherosclerosis
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chemiluminescence (ECL) reagent (Santa Cruz).
(5) Immunohistochemical staining for proliferation.
To detect proliferating cells, immunohistochemical staining
against proliferating cell nuclear antigen (PCNA) were performed
on balloon injured arteries. Briefly, paraffin-embedded samples
were sectioned and treated with protease K for 4 minutes, and
then endogenous peroxidase was quenched with methanol/
peroxidase solution. Specimens were treated with 50 mmol/L
Tris HCl (pH 7.6) containing 0.15 mol/L NaCl and 0.1% Tween
20 for 5 minutes, and then incubated in 1:50 diluted anti-PC-10
antibody (Dako, Cincinnati, OH) for PCNA staining. Specimens
were then processed by incubation with 1:50 diluted 3,39-
diaminobenzidine tetrahydrochloride substrate solution (Dako)
and counterstained with Mayer hematoxylin (Dako). Proliferation
was defined as the percentage of PCNA positive cells versus total
nucleated cells in 4 different sectors per tissue section.
(6) TUNEL staining. Detection of apoptotic cells in vivo was
also performed using the TUNEL method with minor modifica-
tion [23]. Briefly, 5mm sections were deparaffinized and incubated
with proteinase K (Dako) (20 mg/mL) for 15 minutes at room
temperature. An apoptosis detection kit (Apoptag, Intergen
Company) was used with the chromogen DAB. Counterstaining
was done with Mayor hematoxylin (Dako). Apoptotic cells were
quantified by determining percentages of TUNEL-positive cells
versus total nucleated cell count in 4 different sectors per tissue
section.
(7) Immunofluorescence double staining. Immunofluo-
rescence double staining was performed to localize smooth muscle
cells and MMP2-expressing cells by the use of fluorescence-
conjugated antibodies in rat to clarify whether MMP2-positive
cells co-localize on proliferating smooth muscle cells using primary
antibody (rabbit anti-aSMA antibody, 1:50, Dako) and second
antibody (anti-rabbit antibody, 1:50, Dako) for smooth muscle cells
and primary antibody (mouse anti-MMP2 antibody, 1:250, Santa
Cruz) and second antibody (anti-mouse antibody, 1:50, Dako) for
MMP2. Immunofluorescence double staining was also performed
to localize aSMA (Dako) and MMP9 (Dako) to clarify whether
proliferating smooth muscle cells correspond to cells expressing
MMP9.
(8) Glucose metabolism, adiponectin and inflamma-
tory status. Possible relevant factors affecting the degree of
neointimal formation, such as glucose homeostasis, adipocytokines
and inflammatory status were evaluated. For glucose homeostasis,
an intraperitoneal glucose tolerance test (IPGTT) was done at
baseline and 3 weeks after DPP-IV inhibitor treatment. After the
12 h fasting glucose concentration had been measured, each
animal was injected intraperitoneally with 1.5 g/kg of 50 M
glucose solution. Blood samples (about 10 mL) were collected from
an incision in the tail at 30, 60, 90 and 120 min after the glucose
load. Plasma glucose concentration was measured using reagent
strips read in a glucose meter (YSI 2300-STAT, Yellow Springs,
OH). The homeostasis model assessment of the insulin resistance
(HOMA-IR) and beta cell function (HOMA-B) were calculated
using fasting insulin and glucose levels. In addition, the area under
the curve for glucose (AUCglucose) was calculated using the
trapezoid rule for glucose data from 0 to 120 min. Rat adiponectin
and high-sensitivity C-reactive protein (hsCRP) were measured by
using ELISA kits developed by Adiopogen (Seoul, Korea) and BD
Biosciences Pharmingen (Heidelberg, Germany), respectively.
Monocyte chemoattractant protein-1 (MCP-1), TNFa and
plasminogen activator inhibitor-1 (PAI-1) activity were also
measured by a Multiplex kit (RADPK-81K, Linco).
Cell Study
Rat aortic smooth muscle cells (RAoSMCs) were obtained from
Bio-Bud (Seoul, Korea) and cultured in Dulbecco’s modified
Eagle’s medium (Gibco BRL, Grand Island, NY) supplemented
with 10% fetal bovine serum (FBS) and 100 U/mL penicillin-
streptomycin. Primary cultures of human umbilical vein endothe-
lial cells (HUVECs; Cambrex, Walkersville, MD) were cultured in
endothelial cell growth medium (EGM-2; Cambrex) containing
2% FBS, 0.4% hydrocoritisone, 4% hFGF-B, 0.1% VEGF, 0.1%
R3-IGF, 0.1% ascorbic acid, 0.1% hEGF, 0.1% GA-1000, and
0.1% heparin, according to the manufacturer’s instruction. Cells
were grown in an atmosphere of 95% air and 5% CO2 at 37uC.
RAoSMCs were starved in DMEM supplemented without for 48
hours and used for the experiments. HUVECs were starved in
endothelial cell basal medium (EBM-2) (Cambrex) supplemented
with 0.2% FBS for 24 hours and used for the experiments.
Subcultured RAoSMCs from passages 4 to 11 and HUVECs from
passages 2 to 9 were used in this experiment.
(1) Cell proliferation assessed by MTT and thymidine
incorporation assay. Cell proliferation was determined by a
modified 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay. MTT (Sigma) (5 mg/mL) was dissolved
in PBS. RAoSMCs were grown in 48-well plates at a density of
2610
3 per well, and starved for 48 hours, and then placed in
DMEM supplemented with 0.5% FBS. The cells were exposed to
different doses of sitagliptin for 24 and 48 hours. The same
method was used for HUVECs. HUVECs were grown in 48-well
plates at a density of 2610
3 per well. After 24 hours of starvation,
EBM-2 was supplemented with 0.2% FBS. The cells were exposed
to the same dose of sitagliptin for 24 and 48 hours, after 0.5 mL of
MTT solution (5 mg/mL) in starvation medium was added to
each well, and the plates were incubated for 4 hours at 37uCi n5 %
CO2/air. The medium was removed carefully, and the purple dye
was dissolved in 0.1 mL dimethyl sulfoxide. After 10-minute
incubation, 200 mL from each well was transferred to a 96-well
plate, and the absorbance was measured at 570 nm with a
spectrophotometer.
For the thymidine incorporation assay, VSMCs (5610
4 cells)
were seeded in 24-well plates in DMEM with 10% FBS. For
serum-induced or platelet-derived growth factor (PDGF) stimula-
tion, cells were incubated with 2% fetal bovine serum (FBS) or
10 ng/mL of PDGF (R&D Systems, Camarillo, USA) for 24 h,
respectively. Subsequently, [
3H]-thymidine at 1 mCi per well was
incubated for a further 4 h. The incubation was terminated by 5%
trichloroacetic acid (TCA) for 20 min. The fixed cells were then
washed twice with 100% ethanol and treated with 0.3M NaOH in
2% Na2CO3. The tritium content of lysates was counted by
LS6500 Multipurpose Scintillation Counter (Beckman, CA).
(2) Cell migration assessed by wound healing assay.
RAoSMCs were grown to confluence in 6-well plates and then
starved in DMEM with 0.5% FBS for 48 hours. Each well was
divided into a 263 grid. Using a 100–1000 mL pipette tip, a linear
wound was made in each hemisphere of the well. Immediately
after wounding, the medium was changed to starvation medium.
All reagents were mixed in starvation medium. Images were taken
of the intersections of the linear wound and each grid line, which
resulted in 3 fields per well. Cells were allowed to migrate for 24
hours at 37uC. Each field was measured at 24 hours.
(3) Monocyte adhesion assay. U937 cells (ATCC, Rock-
ville, MD) were washed 3 times with serum-free RPMI media and
then resuspended in this medium. U937 cells (1.25610
4) were
added to the HUVEC monolayers stimulated with TNFa (10 ng/
mL) for 18 hours and incubated for 30 minutes at 37uCi n5 %
CO2. Unbound cells were removed by washing 3 times with PBS.
Sitagliptin and Atherosclerosis
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an endothelial cell were counted in 3–5 randomly selected fields of
view in each well by a phase-contrast microscopy.
(4) Measurement of caspase-3 activity. 1610
4 cells were
seeded into microplate and incubated in DMEM with 10% FBS,
then starved in DMEM with 0% FBS for 24 hr. For TNFa
stimulation, the cells were incubated with 10 ng/mL of TNFa
(R&D systems, Camarillo). The cells were treated with 25, 50, 100,
and 200 mg/ml of sitagliptin for 24 h. Caspase-3 activity was
measured by using Caspase-Glo 3/7 assay kit (Promega, WI,
USA).
(5) MMP2 and MMP9 expression in HUVEC. Harvested
cells were solubilized in cell lysis buffer (Cell Signaling). Protein
lysate concentrations were measured using a Bradford protein
assay kit (BioRad). Primary antibodies for MMP2 and MMP9
(both from Santa Cruz) were applied.
(6) Mechanistic experiment with small interfering
RNA (siRNA) against DPP-IV and CARD11. Recently,
Ohnuma et al. have shown that DPP-IV binding to CARD11
induces NFkB activation in T-cells [20]. To determine whether
both of DPP-IV and CARD11 can affect NFkB activation in
VSMCs, we examined the effect of DPP-IV and CARD11
knockdown in VSMCs. Presence of DPP-IV enzyme in VSMCs
was identified by RT-PCR. PDGF-BB and TNFa were used to
check their effects on DPP-IV expression. For knockdown of DPP-
IV, VSMCs were transfected with siDPP-IV (Dharmacon, 50nM)
using Lipofectamine RNAiMAX (Invitrogen). Thymidine incor-
poration assay was performed with siDPP-IV to confirm that
direct inhibition of DPP-IV was involved in attenuated cell
proliferation which was induced by FBS or PDGF-BB. Changes of
NFkB activation by siDPP-IV or sitagliptin were also evaluated in
EMSA study. The effect of sitagliptin on the expression of
CARD11 by RT-PCR in VSMCs was also explored. For
knockdown of CARD11, VSMCs were transfected with si-
CARD11 (Dharmacon, 50 nM) using Lipofectamine RNAiMAX.
Similarly, to investigate involvement of CARD11 in NFkB
pathway, changes of NFkB activation by siCARD11 was
determined by EMSA study. Detailed information of RT-PCR
and EMSA was described in the online supplement.
Statistical Analysis
Results are reported as means 6 SD. Mean values are
compared for the DPP-IV inhibitor treated group and the control
group by ANOVA with the post hoc test, and p , 0.05 is
considered statistically significant (SPSS 12.0, Chicago, IL).
Figure 1. Plasma active GLP-1 (A) and glucagon (B) levels after 3 week treatment of sitagliptin. Plasma active GLP-1 levels increased and
glucagon levels decreased significantly in a dose-dependent manner (*p ,0.05 compared with control and {p ,0.05 compared with 100 mg/kg of
sitagliptin treatment). In vivo inhibition of neointimal formation after 3 weeks of treatment with sitagliptin. C. H&E stained sections of the four groups
(control and sitagliptin groups: 100, 250 and 500 mg/kg). D. Intima-media ratios (IMRs) in the three groups (n = 10 in each group). Treatment with
sitagliptin produced a lower IMR than controls in a dose-dependent manner (the lower IMR with the higher dose of sitagliptin, p , 0.05 between
control and 250 mg/kg or 500 mg/kg of sitagliptin groups).
doi:10.1371/journal.pone.0035007.g001
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(1) Biochemical parameters including plasma active
GLP-1 and glucagon levels, glucose metabolism, adipo-
nectin and inflammatory status after 3 week treatment
of sitagliptin. Plasma active GLP-1 and glucagon levels were
measured at 4 hour post dosing after 3 week treatment of
sitagliptin. Plasma active GLP-1 levels increased and glucagon
levels decreased significantly in a dose-dependent manner (*p ,
0.05 compared with control and {p , 0.05 compared with
100 mg/kg of sitagliptin treatment) (Fig. 1A and 1B).
Three week treatment of sitagliptin reduced postprandial
glucose level significantly and dose dependently, although there
was borderline significance in reduction of fasting glucose level by
sitagliptin treatment (Table 1). There was no difference in
IPGTT findings at baseline (data not shown). However, after 3
weeks treatment of sitagliptin, glucose tolerance was improved in
these animals, as indicated by the significantly decreased
AUCglucose during OGTT in the DPP-IV inhibitor-treated rats
(500 mg/kg of sitagliptin) as compared to the control rats
(Table 1). HOMA-B, which is a surrogate marker of beta cell
function of pancreas, was increased significantly higher in high
dose treatment of sitagliptin than control. Furthermore, the
treatment with sitagliptin induced increasing pattern of plasma
concentration of adiponectin, which is known to be closely
associated with insulin sensitivity. Plasma levels of hsCRP and
MCP-1, well known inflammatory markers, were decreased by the
treatment of DPP-IV inhibitors although statistical significance
was only found between high dose of sitagliptin groups and control
rat (Table 1). Other inflammatory or thrombotic markers (TNFa,
IL6 or PAI-1) were also found to have decreasing patterns by
sitagliptin treatment although there was no statistical significance.
Furthermore, there were significant correlations between inflam-
matory or thrombotic markers and IMR (Fig. S1).
(2) In vivo inhibition of neointimal formation. To
determine whether sitagliptin treatment can alter neointimal
formation, we measured the IMR in H&E stained tissue sections of
injured arteries in OLETF rats. Two weeks after injury, sitagliptin
treated groups (sitagliptin 250 mg and 500 mg) showed a
significant reduction in neointimal formation versus the control
group (Fig. 1C). As shown in Fig. 1D, there was a dose-
dependent relationship in the reduction of IMR among the
sitagliptin treated groups (p , 0.05). A similar but slightly
attenuated result was found in LETO rats (Fig. S2).
(3) DPP-IV and GLP-1 receptor expression in the
carotid artery. The expression of DPP-IV and the GLP-1
receptor was confirmed by Western blotting of the harvested vessel
tissues (Fig. S3A). The expression of DPP-IV and the GLP-1
receptors did not differ significantly between the control and
sitagliptin groups (Fig. S3B and S3C).
(4) Inhibited proliferation and sustained apoptosis of
vascular smooth muscle cells after sitagliptin treatment.
To determine whether sitagliptin can affect cell proliferation
directly, we measured cell proliferation by immunostaining for
PCNA in the 5 tissue sections of injured arteries. As shown in
Fig. 2A, cell proliferation was markedly lower in the sitagliptin-
treated groups than in the controls (open arrow). There was a
dose-dependently decreasing pattern in the proliferation index
among sitagliptin treated groups (Control, 34.2 6 4.1%; sitagliptin
Table 1. Weight, biochemical parameters including glucose homeostasis, lipids, adipocytokines, and inflammatory
markers according to the treatment groups.
Control Sita100 Sita250 Sita500 P
{ Post hoc
{
Weight (g) 588.4 27.4 590.0 32.7 585.8 35.5 597.0 28.4 NS
Fasting glucose (mg/dl) 137.8 25.1 137.3 21.7 126.8 25.9 109.3 15.2 0.069 C,E
Postload glucose (mg/dl) 197.2 26.0 186.4 29.2 184.9 16.2 159.4 16.7 0.022 C,E,F
AUCglucose 579.9 45.0 563.9 42.8 536.1 37.4 521.9 40.4 0.035 B,C
Insulin (pg/ml) 108.6 50.8 119.4 61.0 90.2 40.1 97.1 10.4 NS
HOMA-IR 38.4 22.6 42.3 27.0 27.7 11.7 26.4 6.3 NS
HOMA-B 535.4 214.3 571.6 209.3 578.6 296.1 796.4 151.7 NS C
QUICKI 0.15 0.01 0.15 0.01 0.16 0.01 0.16 0.01 NS
Total C (mg/dl) 77.4 11.2 88.0 21.5 72.1 12.3 81.2 22.2 NS
Triglycerides (mg/dl) 92.7 32.9 90.5 23.0 66.3 27.1 70.2 35.3 NS
HDL-C (mg/dl) 24.7 3.0 26.1 5.7 23.4 7.9 27.8 7.1 NS
LDL-C (mg/dl) 35.4 5.2 43.8 14.1 35.5 6.2 37.4 7.0 NS
Adiponectin (mg/ml) 8.0 1.7 9.1 3.2 10.3 2.6 12.5 3.7 0.021 C,E
HsCRP (mg/l) 0.19 0.06 0.17 0.05 0.15 0.06 0.12 0.05 0.093 C
TNFa (pg/ml) 5.8 2.0 5.2 1.7 4.6 1.7 4.2 1.9 NS
IL6 (pg/ml) 12.1 5.4 13.3 6.0 11.1 4.3 10.1 2.9 NS
MCP-1 (pg/ml) 162.1 61.6 144.8 37.1 115.8 39.6 107.7 32.1 0.073 B,C
PAI-1 (pg/ml) 224.4 72.0 263.8 96.9 187.8 83.6 171.9 52.8 NS E
Data are means6S.D, Key: sita, sitagliptin; AUCglucose, Area under the curve of glucose; HOMA-IR and HOMA-B, homeostasis model assessment of insulin resistance
and b-cell function; QUICKI, quantitative insulin check index;
{Statistical significance by oneway analysis of variances among groups.
{Post hoc analysis by least significant difference t test (mean difference between two groups: A = Control vs. sita100, B = Control vs. sita250, C = Control vs. sita500, D
= sita100 vs. sita250, E = sita100 vs. sita500, F = sita250 vs. sita500, P , 0.05 in all cases).
doi:10.1371/journal.pone.0035007.t001
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500 mg, 7.6 6 2.1%, P for trend , 0.01) (Fig. 2C).
To examine the effects of sitagliptin treatment on apoptosis
after balloon injury in vivo, we performed TUNEL staining in the
5 tissue sections of injured arteries (Fig. 2B). After three weeks
treatment of sitagliptin (at two weeks after balloon injury), the
apoptosis index was increased significantly in the sitagliptin
groups compared to the control group, which was in a dose-
dependent manner among sitagliptin treated groups (9.5 6 1.7%
in sitagliptin 100 mg, 18.4 6 2.9% in sitagliptin 250 mg and
22.4 6 2.2% in sitagliptin 500 mg compared to control, P for
trend , 0.01) (Fig. 2D). Using double staining for a-smooth
muscle actin and TUNEL, we identified the apoptotic cells as
smooth muscle cells; there were more vascular smooth muscle
cell apoptotic bodies in the sitagliptin treated group than in
control group (p , 0.01) (Fig. S4).
(5) Decrease in MMP2 and MMP9 expression in
sitagliptin treatment groups. To clarify whether proliferating
smooth muscle cells correspond to the cells expressing MMP2, we
performed double-staining with the anti-aSMA antibody (red) and
anti-MMP2 antibody (green) (Fig. 3A) or anti-MMP9 antibody
(green) (Fig. 3C) in injured arteries. Nucleus of cells was stained by
DAPI (blue). Fewer MMP2-expressing cells (Fig. 3B) and MMP9-
expressing cells (Fig. 3D) were observed in the sitagliptin treated-
groups than in the control groups, and the effects were dose-
dependent.
Figure 2. Effects of sitagliptin treatment or normal saline as a control on proliferation and apoptosis of vascular smooth muscle
cells. A. Cell proliferation measured by immunostaining for proliferating cell nuclear antigen (PCNA) was markedly lower in the sitagliptin-treated
groups than in the controls (open arrow). B. TUNEL staining of the three groups (open arrow). C. The proliferation index was significantly lower in the
sitagliptin-treated groups than in the control group. There was a dose-dependent pattern in the level of proliferation between sitagliptin-treated
groups (*p , 0.05 vs. control and {p , 0.05 vs. sitagliptin 100 mg/kg). D. Apoptosis index (%) at 2 weeks after balloon injury. Apoptosis was
significantly higher in the sitagliptin -treated groups than in the control group, and there was a dose-dependent pattern in the level of apoptosis
between sitagliptin-treated groups (*p , 0.05 vs. control and {p , 0.05 vs. sitagliptin 100 mg/kg).
doi:10.1371/journal.pone.0035007.g002
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(1) Proliferation and migration of VSMCs and mono-
cyte adhesion in vitro after sitagliptin treatment. In MTT
assays, sitagliptin treatment inhibited PDGF-BB-induced cell
proliferation in RAoSMCs (Fig. 4A). This effect was initiated at
the dose of 50 mM and was increased dose dependently to be more
prominent at the dose of 200 mM. Similar finding was found in the
thymidine incorporation assay (Fig. S5). Sitagliptin treatment also
inhibited TNFa-directed migration of RAoSMCs in a dose-
dependent manner from 50 to 200 mg/mL (Fig. 4B, 4C). To test
whether sitagliptin can prevent TNFa-induced monocyte adhe-
sion, we performed the monocyte adhesion assay by using U937
cells. TNFa treatment significantly increased monocyte adhesion
in U937 cells, and these effects were blocked by treatment of
sitagliptin in a dose-dependent manner (Fig. 4D, 4E). This
Figure 3. Immunofluorescent double staining for MMP2 (A) and MMP9 (C) expressing cells in tissue sections of injured arteries.
Double-staining was done with the anti-aSMA antibody (red) and anti-MMP2 or MMP9 antibody (green). Nucleus of cells was stained by DAPI (blue).
MMP2 and MMP9 expressions were reduced by sitagliptin treatment (500 mg/kg) compared to control. Two scaled photos were displayed (6100 and
6400). Effect of sitagliptin on MMP2 (B) and MMP9 (D) expression in tissue sections of injured arteries (*p , 0.01 compared with control and {p ,
0.01 compared with 100 mg/kg of sitagliptin treatment).
doi:10.1371/journal.pone.0035007.g003
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cytotoxicity, as shown by the calcein measurement and WST-8
assay (Fig. S6A and S6B).
(2) Change of caspase-3 activity after sitagliptin
treatment. Apoptosis, a type of programmed cell death, is one
method of controlling immune responses such as cellular
homeostasis as well as a variety of physiological processes.
Caspases, a family of cysteine proteases, play a central role in
the apoptosis [24]. TNFa is secreted by VSMCs in the neointima
after a balloon injury as well as by macrophages in atherosclerotic
lesions [25]. Therefore, the effect of sitagliptin treatment on
caspase-3 activity was investigated in TNFa-stimulated VSMCs.
Sitagliptin treatment increased the level of caspase-3 activity in a
dose-dependent manner, reflecting apoptosis in RAoSMCs (Fig.
S7).
(3) Effect of sitagliptin on MMP2 and MMP9
expression in HUVECs and VSMCs. Increased proteolytic
activity in the vessel wall mediates the degradation of the ECM
surrounding smooth muscle cells in response to injury [26], a
necessary step to allow medial smooth muscle cells to migrate into
the intimal space. Matrix metalloproteinases (MMPs) such as
MMP2 (72 kDa) and MMP9 (92 kDa), have been implicated as
mediator of lesion development in response to vascular injury
[27,28]. The effect of sitagliptin on MMP2 and MMP9 expression
was examined in HUVECs and VSMCs. Expression of MMP2
and MMP9 decreased significantly in a dose-dependent manner
after treatment with sitagliptin compared with TNFa treatment (p
, 0.01) (Fig. S8 and Fig. S9).
(4)EffectofDPP-IVandCARD11knockdowninVSMCs.
DPP-IV was expressed in VSMCs and was knockdowned by
siDPP-IV (Fig. 5A). The expression of DPP-IV was not changed
by treatment of PDGF-BB or TNFa. FBS- or PDGF-BB-induced
cell proliferation was significantly attenuated by siDPP-IV
transfection (Fig. 5B). Attenuation of TNFa- or PDGF-BB-
induced NFkB activation by siDPP-IV transfection was also
confirmed in EMSA assay (Fig. 5C). TNFa-induced NFkB
activation was attenuated by sitagliptin treatment dose-depen-
dently (Fig. 5D). Expression of CARD11 was decreased dose-
dependently by sitagliptin treatment in VSMCs (Fig. 5E).
CARD11 was expressed in VSMCs and its expression was
knockdowned by siCard11 (Fig. 5F). TNFa-induced NFkB
activation was decreased by siCARD11 transfection in EMSA
assay (Fig. 5G).
Figure 4. Effects of sitagliptin on proliferation and migration of rat aortic smooth muscle cells (RAoSMC). A. In MTT viability assays, cell
proliferation was significantly decreased by sitagliptin treatment (*p , 0.05 compared with PDGF-BB only). B. TNFa-directed migration with
sitagliptin treatment. C. Dose-dependent inhibiting pattern of TNFa-directed migration from 50 to 200 mg/mL (*p , 0.05 compared with TNFa
treatment). D. Effects of sitagliptin on TNFa-stimulated monocyte adhesion using U937 cells. Open arrows indicate adhered monocytes. E. Dose-
dependent inhibiting pattern of TNFa-stimulated monocyte adhesion (*p , 0.05 compared with TNFa treatment).
doi:10.1371/journal.pone.0035007.g004
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The current study demonstrated that treatment with des-fluoro-
sitagliptin, a DPP-IV inhibitor, reduced restenosis in obese type 2
diabetic rats following balloon injury to the carotid artery. In vivo
and in vitro studies revealed that sitagliptin treatment suppressed
proliferation of VSMCs, promoted apoptosis and reduced
inflammatory process. Sitagliptin therapy also reduced hsCRP
and MCP-1 levels and increased adiponectin concentration,
indicating decrease of markers of inflammation and procoagula-
tion, and increase of insulin sensitivity. These findings suggest that
sitagliptin has protective role of development of macrovascular
complication, supporting an emerging role of sitagliptin in
modifying the elevated cardiovascular risks that are inherent in
obesity and type 2 diabetes.
Interestingly, it was recently demonstrated that GLP-1 amelio-
rates endothelial dysfunction in type 2 diabetes mellitus patients
with established coronary heart disease, suggesting a new
important cardioprotective role for GLP-1 [29,30]. In other study,
GLP-1 infusion significantly increased relative changes in brachial
artery diameter from baseline flow mediated dilatation (%) (3.1 6
0.6 vs. 6.6 6 1.0%, p , 0.05) in type 2 diabetes patients with
coronary artery disease [29], just as GLP-1 increased intracellular
cAMP (from 5.7 6 0.5 to 13.1 6 0.12 pmol/mg protein) in rat
cardiac myocytes [31]. Considering inhibition of DPP-IV has been
demonstrated to increase concentrations of intact GLP-1 2–3 fold
in patients with type 2 diabetes [3], it is conceivable that sitagliptin,
a potent and highly selective DPP-IV inhibitor, improves
endothelial dysfunction as a result.
In addition, it is well known that infiltration of inflammatory
cells occurs early after endothelial denudation [32–35]. Inhibition
of this process has been reported to be associated with a reduction
in medial VSMC proliferation [33]. Considering previous studies
showing linear relationship between tissue monocyte content and
neointimal area [35] and decreased neointimal thickening through
blocking early monocyte recruitment by anti-inflammatory drug
[36], inflammatory response related with monocyte infiltration
could be a causative factor in restenosis.
In the current study, sitagliptin treatment also reduced MMP2
and MMP9 expression in tissue sections in injured arteries. The
MMPs are a family of molecules that are associated with the
breakdown of constituents of the ECM. Both MMPs and their
tissue inhibitors are involved in the regulation of the ECM
metabolism [37]. ECM is a dynamic structure that requires
constant synthesis and degradation by MMPs [38]. Either MMP2
or MMP9 are synthesized and secreted locally in atherosclerotic
lesions, predominantly by monocyte-derived macrophages and
endothelial cells [39] and may participate in rupture of the
atherosclerotic plaque [40]. Type 2 diabetic patients are at high
risk for acute coronary events due to an increased propensity of
Figure 5. Mechanistic experiment with small interfering RNA (siRNA) against DPP-IV and CARD11. A. DPP-IV expression in VSMCs. The
DPP-IV expression was knockdowned by siDPP-IV while it was not changed by treatment of PDGF-BB or TNFa. B. FBS- or PDGF-BB-induced cell
proliferation was significantly attenuated by siDPP-IV transfection. C. Attenuation of TNFa- or PDGF-BB-induced NFkB activation by siDPP-IV
transfection was also confirmed in EMSA assay. D. TNFa-induced NFkB activation was attenuated by sitagliptin treatment dose-dependently. E.
Expression of CARD11 was decreased dose-dependently by sitagliptin treatment in VSMCs. F. CARD11 was expressed in VSMCs and its expression was
knockdowned by siCARD11. G. TNFa-induced NFkB activation was decreased by siCARD11 transfection in EMSA assay.
doi:10.1371/journal.pone.0035007.g005
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thrombosis [41], and have increased level of MMP2 and MMP9
[14]. Thus, as shown in our study, the reduction of MMP2 and
MMP9 may be a possible mechanism in preventing macrovascular
complications in patients with type 2 diabetes by sitagliptin
treatment.
MCP-1, which is an important factor of monocyte recruitment,
has been shown to play a pivotal role in the development of
atherosclerosis and involves a sequence of events that include
monocyte attraction, tethering and rolling, and firm adhesion
[36,42]. Recently it has been described that blocking of the MCP-1
pathway results in reduced atherosclerosis and restenosis by
inhibitionofmonocyte adhesiontothe vascular walland toreduced
macrophage content in the atherosclerotic lesion [36]. In this study,
sitagliptintreatmentsignificantlyanddose-dependentlyreducedthe
degree of monocyte adhesion and showed decreasing pattern of
serum concentration of MCP-1. These findings suggest another
mechanism by which sitagliptin has beneficial effect on counteract-
ing restenosis. In addition, such infiltrations of inflammatory cells
are known to promote an atherosclerotic milieu [32,43,44].
Whether sitagliptin has the ability to positively influence athero-
sclerotic plaque formation would warrant further investigation.
NFkB is a common regulator that involves in the control of
proinflammatory genes and VSMCs proliferation. It has been
reported that DPP-IV interacting with CARD11 or CARMA1
leads to NFkB activation in T-cells [20]. In the present study,
NFkB activation was reduced by DPP-IV or CARD11 Knock-
down, and attenuated dose-dependently by sitagliptin treatment in
VSMCs. Proliferation of VSMCs was inhibited by siDPP-IV
transfection and sitagliptin treatment. These results indicate that
gene expression of DPP-IV as well as enzyme activity of DPP-IV
plays a crucial role in NFkB activation. Thus, reduction of NFkB
activation by siDPP-IV and sitagliptin could be a major
mechanism in decrease of VSMCs proliferation.
Other possible relevant factors affecting the degree of
neointimal formation were considered in this study. Glucose
lowering effect by sitagliptin treatment might contribute to this
but sitagliptin were treated only for 3 weeks. Circulating levels
of adiponectin were increased significantly in sitagliptin
treatment in a dose-dependent manner. Low adiponectin level
is a risk factor for the subsequent development of cardiovascular
diseases [17,19]. Further, high dose of sitagliptin induced
decreasing pattern of hsCRP and PAI-1 activity in this study
although statistical significance was not obtained. This finding is
in line with a recent study describing that GLP-1 treatment
attenuated mRNA expression by TNFa and induction of PAI-1
protein [45]. In the latter study, GLP-1 also inhibited the effect
of TNFa on a reporter gene construct harboring the proximal
PAI-1 promoter.
In conclusion, this study, in addition to glucose lowering effects,
demonstrates that sitagliptin, a DPP-IV inhibitor, has protective
properties against restenosis after carotid injury in an animal
model of type 2 diabetes and vascular cell lines. These finding raise
the possibility that sitagliptin could offer a novel agent for the
treatment of macrovascular-related complications in patients with
type 2 diabetes.
Supporting Information
Figure S1 Correlations between intima-media ratio
(IMR) and hsCRP, TNFa and MCP-1 levels and PAI-1
activity. There were positive correlations between IMR and each
factor (p , 0.05 except IMR vs. PAI-1 activity).
(TIF)
Figure S2 In vivo inhibition of neointimal formation
after 3 weeks of treatment with des-fluoro-sitagliptin in
LETO rats. A, H&E-stained sections of the control and
sitagliptin (500 mg/kg) groups. B, Intima-media ratios (IMRs) in
the two groups (n = 10 in each group). The IMR was calculated
from the mean areas of the intima and media. Treatment with
sitagliptin produced a lower IMR than in controls (p , 0.05
between the control and 500 mg/kg sitagliptin-treated groups).
(TIF)
Figure S3 A. Western blot of DPP-IV and GLP-1 receptor
in the injured carotid arteries of control and sitagliptin
treated rats. Representative three samples were displayed.
Quantification of Western blot images of DPP-IV (B) and GLP-1
receptor (C).
(TIF)
Figure S4 Double staining of a-smooth muscle actin
(aSMA) and TUNEL in the injured carotid vessel wall.
Apoptotic cells were smooth muscle cells; there were more
vascular smooth muscle cell apoptotic bodies in the sitagliptin
treated group (18.7%) than in the control group (5.2%) (p , 0.01)
(Arrows indicate vascular smooth muscle cell apoptotic bodies).
(TIF)
Figure S5 Thymidine incorporation assay to check
effect of sitagliptin on FBS- or PDGF-induced cell
proliferation. There were dose-dependent decreasing patterns
of thymidine uptake by sitagliptin treatment (*p , 0.05 compared
with FBS or PDGF-BB treatment only).
(TIF)
Figure S6 Effect of sitagliptin on cell survival. A. Calcein-
acetoxymethyl ester (calcein-AM) cell viability assay kit was used
(Biotium, Hayward, CA, USA). Cells were washed with PBS and
incubated with 2 mM calcein AM for 30 min. The fluorescence
was measured using 485 nm excitation wavelength and 530 nm
emission wavelength with a Victor 3 instrument (Perkin-Elmer,
Boston, MA, USA). B. Cell viability was also measured with Cell
Counting Kit-8 (CCK-8, Dojindo, Japan). Absorbance was
measured at 450 nm (VersaMax; Molecular Devices, Sunnyvale,
CA, USA). Cell Counting Kit-8 (CCK-8) allows convenient assays
by utilizing Dojindo’s highly water-soluble tetrazolium salt. WST-
8 [2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-
phenyl)-2H-tetrazolium, monosodium salt] produces a water-
soluble formazan dye upon reduction in the presence of an
electron carrier. WST-8 is reduced by dehydrogenases in cells to
give a yellow-colored product (formazan), which is soluble in the
tissue culture medium. The amount of the formazan dye
generated by the activity of dehydrogenases in cells is directly
proportional to the number of living cells.
(TIF)
Figure S7 Induction of apoptosis shown by the activa-
tion of caspase-3 with sitagliptin treatment in VSMCs.
There was a dose-dependent increasing pattern of caspase-3
activity (*p , 0.05 compared with TNFa treatment only).
(TIF)
Figure S8 Effects of sitagliptin on MMP2 and MMP9
expression levels in human umbilical vein endothelial
cells (A). Expressions of MMP2 (B) and MMP9 (C) decreased
significantly with the treatment of sitagliptin compared to TNFa
treatment in a dose-dependent manner (*p , 0.05 compared with
TNFa treatment).
(TIF)
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expression levels in vascular smooth muscle cells (A).
Expressions of MMP2 (B) and MMP9 (C) decreased significantly
with the treatment of sitagliptin compared to TNFa treatment in a
dose-dependent manner (*p , 0.05 compared with TNFa
treatment).
(TIF)
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